Quanterix shares dropped 16.7% after earnings as investors reacted negatively to softer-than-expected instrumentation sales and a cautious near-term outlook, despite ongoing investments and operational changes that have yet to deliver clear growth.

• Q1 revenue totaled $36.4 million, with consumable sales meeting plans but instrumentation revenue coming in below expectations.
• Management attributed weaker instrument sales partially to timing issues but acknowledged the need for sharper sales focus and commercial investments.
• The company is increasing investments in leadership and go-to-market capabilities to drive pharma partnerships and new business development.
• Gross margins and cash usage targets were maintained, reflecting operational discipline despite top-line pressures.
• Quanterix emphasized long-term growth initiatives, particularly in Alzheimer’s diagnostics, but these remain early-stage without immediate financial impact.